Rather, NOAF has been affected mostly by; First, inflammation biomarkers such as CRP, which have previously been linked to AF; secondly, laboratory biomarkers such as d‐dimer and Troponin‐I, which correspond with the severity of COVID‐19 disease; and thirdly, administering corticosteroids, which, quite apart from potential drug effect, is commonly directed against those exhibiting the greatest hyperinflammation response. The gene discussed is CRP; the disease is atrial fibrillation.